Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-07-22 Capital/Financing Update
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Updates
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Concord Biotech Limited to stock exchanges regarding the incorporation of a wholly owned subsidiary company, Concord Lifegen Limited. It includes detailed disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to material events or information. The content focuses on the incorporation and related details of the subsidiary, including share capital, business objectives, and regulatory compliance. There are no financial statements or performance data presented, nor is this a report or presentation. This fits the category of a Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through the creation of a subsidiary and investment therein.
2025-07-22 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges regarding the completion of a European Union Good Manufacturing Practices (EU GMP) inspection at the company's manufacturing facility. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The document does not contain financial data, audit results, or detailed report content but is an informational disclosure about a regulatory inspection outcome. It is short (2037 characters) and serves as a notification rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended June 30, 2025. It is addressed to stock exchanges and is a compliance certificate from the registrar and share transfer agent. The document is short (4041 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-08 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding an equity investment in Stellon Biotech Inc. It details the subscription of shares, percentage ownership acquired (75%), and the purpose of the acquisition to expand business operations in the USA. The document references compliance with SEBI LODR Regulations and includes an annexure with detailed information about the target entity, the nature of the transaction, and other regulatory disclosures. There are no financial statements or quarterly/yearly financial results presented. The document is an announcement of a capital investment and acquisition activity, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-07-02 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying the closure of the trading window pursuant to SEBI regulations ahead of the announcement of unaudited quarterly financial results. It does not contain any financial data or results itself, nor does it present a report. The document is an announcement related to compliance and insider trading restrictions before the release of quarterly results. Given the short length (2468 characters) and the nature of the content, it is not a financial report but a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS).
2025-06-25 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement from Concord Biotech Limited addressed to stock exchanges regarding the receipt of an Establishment Inspection Report (EIR) from the US FDA for their API facility inspection. It states the inspection is closed with no regulatory action required. The document is brief (1932 characters) and serves as a regulatory update rather than a detailed report or financial filing. It does not contain financial data, management discussion, or detailed audit information. It is an official regulatory announcement about inspection results, fitting best under Regulatory Filings (RNS).
2025-06-24 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.